相关实验视频

Updated: Jul 28, 2025

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Tracking Bispecific Antibody-Induced T Cell Trafficking Using Luciferase-Transduced Human T Cells

Published on: May 12, 2023

一个设计师的策略是开发新的双特异性癌症治疗抗体

Rakesh Kumar^1,2,3

¹Cancer Research Institute, Himalayan Institute of Medical Sciences, Swami Rama Himalayan University, Dehradun, India.

Clinical cancer research : an official journal of the American Association for Cancer Research

|June 2, 2023

概括

研究人员开发了一种针对EPHA2和表皮生长因子受体 (EGFR) 的新型双特异性抗体. 这种抗体有效地抑制了癌细胞的生长,并提供了针对EGFR治疗耐药性的新策略.

科学领域:

在瘤学瘤学.
免疫治疗是一种免疫疗法.
分子生物学分子生物学

背景情况:

针对癌症的向疗法,特别是那些涉及受体氨酸激酶 (如EPHA2和EGFR) 的疗法,面临局限性.
开发有效的治疗抗体,可以选择性地准这些受体,或它们的组合,仍然是一个挑战.

研究的目的:

发现和设计一种能够共同向EPHA2和EGFR的新型双特异性治疗抗体.
在临床前癌症模型中评估这种新抗体的疗效.

主要方法:

使用了蛋白质基因组分析,ex vivo癌症模型和短毛RNA (shRNA) 查的组合.
设计并测试了一种双特异性抗体,该抗体被设计用于结合EPHA2和EGFR.

主要成果:

新设计的双特异性抗体在各种临床前癌症模型中显著抑制了瘤细胞生长.
该抗体显示出克服对现有EGFR导向疗法的获得性耐药性的潜力.

结论:

一种新型双特异性抗体成功开发出来,可以共同向EPHA2和EGFR.
这种抗体代表了治疗人类瘤的有希望的新疗法工具,可能通过解决对EGFR抑制剂的耐药性机制.

更多相关视频

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

A GPC3-targeting Bispecific Antibody, GPC3-S-Fab, with Potent Cytotoxicity

Published on: July 12, 2018

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Hybridoma Technology

Hybridoma Technology

Hybridoma technology is used for the large-scale production of monoclonal antibodies. Monoclonal antibodies bind to only a single antigenic determinant or epitope. Such antibodies are used in research, diagnostics, and disease therapy. The hybridoma technology established in 1975 by Georges Köhler and Cesar Milstein was awarded the Nobel Prize in Medicine in 1984 for revolutionizing research and therapy.
Hybridoma Selection
Commonly used fusion techniques — electroporation,...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...